Document:

Blueprint

 

Exhibit 10.1

 

Facility Improvement and Process Validation Agreement

 

This
facility improvement and process validation agreement
("Agreement") is effective
this 26th day of August, 2019 ("Effective Date") and is between Duke
University, a tax-exempt research and educational institution
located in Durham, North Carolina, acting for and on behalf of its
School of Medicine (“Duke”), and Cellular Biomedicine
Group, Inc. ("Sponsor") a
corporation with offices in 1345 Avenue of the Americas,
15th
Floor, New York, New York 10105. The parties represented in this
Agreement shall be referred to individually as a
“Party” and collectively as the
“Parties”.

 

WHEREAS, Duke has established a
biological manufacturing facility capable of producing cellular
products under current Good Manufacturing Practice regulations
(“Core
Lab”) to promote and
support scientific research and;

 

WHEREAS, Duke requires facility improvements to provide for
greater Core Lab capacity anticipated to be used by Duke in future
research funded by Sponsor;

 

WHEREAS, both Parties desire
for such Core Lab to collaborate on a clinical trial of tumor
infiltrating lymphocytes (TIL cells) that will be performed at Duke
and funded by Sponsor; and

 

WHEREAS, the facility improvements contemplated by this
Agreement are of mutual interest and benefit to Duke and Sponsor and will further the instructional
and research objectives of Duke
in a manner consistent with its status as a non-profit education
and health care institution.

 

NOW, THEREFORE, the Parties agree as follows:

 

1. 

Duke
shall conduct the project described in Exhibit A, attached (the
“Project”).

 

2. 

Duke’s Investigator ("Investigator") shall be Joanne
Kurtzberg, M.D., who will oversee the Project. If the Investigator
is unable to continue to serve and a successor acceptable to both
Duke and Sponsor is not available, this Agreement
will be terminated in accordance with Article 7.

 

3. 

In consideration of
the performance of the Project, and as detailed in the budget
included as Exhibit B, Sponsor shall pay Duke a fixed-price total
of [***]. Upon submission of an invoice by Duke, Sponsor will pay
the full amount within forty-five (45) days of the Effective
Date.

 

4. 

Duke’s relationship to Sponsor under this Agreement shall be that
of an independent contractor and not an agent, joint venturer,
employee, or partner of Sponsor.

 

5. 

The Project will
commence of the Effective Date and will terminate upon completion
of the Project or twenty-four (24) months from the Effective Date,
whichever is sooner (the “Term”). The Parties may extend the
Term of this Agreement upon execution of a written amendment to
this Agreement.

 

 

1

 

 

 

 

6. 

Confidential
information shall mean all information provided by one Party (the
“Disclosing
Party”) to the other (the “Receiving Party”) that is clearly
identified in writing as confidential by the Disclosing Party at
the time of disclosure (“Confidential Information”). The
Receiving Party agrees to hold the Disclosing Party’s
Confidential Information in trust and confidence, using the same
care and discretion that the Receiving Party uses with information
that it considers confidential. The Receiving Party will not use
the Disclosing Party’s Confidential Information for purposes
other than those contemplated by this Agreement. The Receiving
Party shall not be bound by confidentiality obligations hereunder
with respect to the Confidential Information, or any part thereof,
that:

(a) is
already known to the Receiving Party at the time of the
disclosure;

(b) is
or becomes publicly known without the wrongful act or breach of
this Agreement by the Receiving Party;

(c) is
rightfully received by the Receiving Party from a third party on a
non-confidential basis;

(d) is
approved for release by written authorization of the Disclosing
Party; or

(e) is
subsequently and independently developed by employees of the
Receiving Party without use of or reliance upon the Confidential
Information.

 

Nothing
herein shall prevent the Receiving Party from disclosing
Confidential Information to the extent required pursuant to a
judicial or government request, requirement or order. In such
instances, the Receiving Party shall take reasonable steps to
provide the Disclosing Party sufficient prior written notice in
order for the Disclosing Party to contest such request, requirement
or order.

 

7. 

[***] developed by
Duke in the performance of the
Project (the “Results”) shall be promptly and
fully disclosed to Sponsor, and
may be used by Sponsor for any
legitimate purpose. Duke shall
have the right to retain copies of and use all Results for its
own research, educational, clinical,
and publication purposes subject to the confidentiality and
publication review obligations of this Agreement. [***]
shall remain the property of Duke whether developed prior to or during
the Project. During performance of the Project and performance of a
future clinical trial funded by
Sponsor, [***] will be implemented and disclosed to Sponsor.
[***] To the extent Duke has rights in such [***], Duke grants
Sponsor the fully paid-up, non-exclusive, world-wide right to make,
have made, use, have used, and sublicense such [***] for any
legitimate purpose.

 

THE
RESULTS ARE PROVIDED BY DUKE TO SPONSOR “AS IS”. DUKE
MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE,
OR THAT THE USE OF THE RESULTS WILL NOT INFRINGE ANY PATENT,
COPYRIGHT, TRADEMARK, OR OTHER RIGHTS.

 

8. 

Sponsor agrees to
indemnify, hold harmless, and defend Duke, its officers, employees,
and agents against any and all claims, suits, losses, damages,
costs, fees, and expenses asserted by third parties, both
government and non-government, resulting from or arising out of
this Agreement; provided, however, that Sponsor shall not be
responsible for Duke's gross negligence or willful misconduct.
Sponsor shall maintain in force at its sole cost and expense, with
reputable insurance companies, insurance of a type and in an amount
reasonably sufficient to protect against liability hereunder. Duke
shall have the right to request the appropriate certificates of
insurance from Sponsor for the purpose of ascertaining the
sufficiency of such coverage.

 

 

2

 

 

 

 

9. 

Neither Party will,
without the prior written consent of the other Party: (a) use in
advertising, publicity or otherwise, the name of any employee or
agent, any trade-name, trademark, trade device, service mark,
symbol, or any abbreviation, contraction or simulation thereof
owned by the other Party, or (b) represent, either directly or
indirectly, that any product or service of the other Party is a
product or service of the representing Party or that it is made in
accordance with or utilizes the information or documents of the
other Party. Notwithstanding the foregoing, Duke may acknowledge
the contributions of Sponsor in academic publications prepared in
accordance with Article 9 and shall have the right to post
Sponsor’s name, the Project name, and the Project period on
Duke’s publically accessible lists of research conducted at
Duke and as may be required in submissions to funding
agencies.

 

10. 

Any notice or other
communication required or permitted under this Agreement will be in
writing and will be deemed given as of the date it is: (a)
delivered by hand, or (b) mailed, postage prepaid, first class,
certified mail, return receipt requested, to the Party at the
address listed below or subsequently specified in writing, or (c)
sent, shipping prepaid, return receipt requested, by national
courier service, to the Party at the address listed below or
subsequently specified in writing:

 

	

As to Duke:

	

Office of Research Contracts

	
 

	

Duke University,

	
 

	

2200 West Main St. Suite 900,

	
 

	

Durham, N.C. 27705

	
 

	

Attn: Director

	
 

	
 

	

As to Company:

	

Cellular Biomediciane Group, Inc.

	
 

	

1345 Avenue of the Americas, 15th Floor

	
 

	

New York, New York 10105

	
 

	

Chief Legal Officer

11. 

Termination

(a) 

This Agreement will
terminate upon completion of the Project or expiration of the Term,
whichever is sooner.

 

(b) 

The Parties agree
that the provisions of this Agreement are intended to be
interpreted and implemented so as to comply with all applicable
laws, governmental rules and regulations; however, if it is
determined that any provision of this Agreement is not in such
compliance, then the Parties agree to modify that provision or this
Agreement so as to be in compliance. If such modification is not
possible, or practical, or if the Parties are unable to agree upon
the modification to be made, then either Party may immediately
terminate this Agreement.

 

(c) 

Either Party may
terminate this Agreement upon thirty (30) days written notice i) if
the other Party’s breach of this Agreement remains uncured
for such thirty (30) day period, or ii) if the Duke Investigator is
unable to complete the Project and the Parties are unable to agree
upon a successor.

 

(d) 

Either Party may
terminate this Agreement immediately if the other Party engages in
fraud or illegal conduct during the performance of the
Project.

 

(e) 

In the event of
early termination, Sponsor will compensate Duke for i) all
uncompensated milestones met and ii) portions of each milestone
undertaken but not met, on a pro-rated basis, prior to the date of
written notice of termination by Sponsor.

 

(f) 

Upon termination
for any reason, a Party, at the other Party’s discretion,
shall return or destroy all Confidential Information received from
the other Party. A Party may retain in its office of counsel one
(1) copy of the Disclosing Party’s Confidential Information
as record of obligation.

 

 

 

3

 

 

12. 

Nonperformance by
either Party shall be excused to the extent that performance is
rendered impossible by strike, fire, earthquake, flood,
governmental acts or orders or restrictions, failure of suppliers
or any other reason where failure to perform is beyond the
reasonable control of the non-performing Party. In such event the
affected Party, as the case may be, shall promptly notify the other
Party of such inability and of the period for which such inability
is anticipated to continue. Without limiting the foregoing, the
Party subject to such inability shall use reasonable efforts to
minimize the duration of any force majeure event.

 

13. 

Any and all
provisions of this Agreement which by their nature or effect are
required or intended to be observed, kept or performed after
termination or expiration of this Agreement will survive the
termination or expiration of this Agreement, as the case may be,
and remain binding upon and for the benefit of the Parties
hereto.

 

14. 

This Agreement and
its attached Exhibits represent the entire understanding between
the Parties, and supersedes all agreements, express or implied,
between the Parties as to its subject matter. Any alteration,
modification, or amendment to this Agreement must be in writing and
signed by both Parties.

 

15. 

This Agreement is
binding upon and will inure to the benefit of the Parties hereto
and their respective successors and assigns. This Agreement shall
not be assignable in whole or in part by a Party without the prior
written consent of the other Party, such consent not to be
unreasonably withheld. Notwithstanding the foregoing, Sponsor may
assign its rights or obligations under this Agreement in connection
with a merger or similar reorganization or the sale of all or
substantially all of its assets or of the Sponsor’s subject
matter of this Agreement, without the prior written consent of
Duke. Upon completion of such an event, Sponsor will provide Duke
with written notification disclosing the name and address of the
third party that has assumed Sponsor’s rights and obligations
under this Agreement.

 

16. 

This Agreement
shall be governed by the laws of the State of North Carolina,
without reference to its choice of law provisions. The Parties
hereby submit to the jurisdiction of the courts of North Carolina
in all matters concerning this Agreement.

 

 

4

 

 

      WHEREFORE,
the Parties hereto agree:

 

	

             
DUKE UNIVERSITY

 

 

By:                  
  /s/ W. Gavin
Foltz

Printed
Name:    W. Gavin Foltz, J.D.

Title:
                
Assoc. Dean

                                      
  Office of Research Contracts

Date
executed:  August 26, 2019

 

	

CELLULAR
BIOMEDICINE GROUP, INC.:

 

 

By:                  
/s/ Bizuo (Tony)
Liu

Printed
Name:  Bizuo (Tony) Liu

Title:                
Chief Executive Officer

 

 

Date
executed:  August 27, 2019 

 

 

 

 

 

 

5

 

 

EXHIBIT A

 

Scope of Work

 

 

[***]

 

 

 

 

 

6

 

 

EXHIBIT B

 

Budget

 

 

[***]

 

 

 

 

 

7Exhibit 4.3

 

 

 

 

 

newmont
GOLDCORP corporation, 

as Issuer, 

 

Newmont
USA Limited, 

as Guarantor,

 

and

 

The
Bank of New York Mellon Trust Company, N.A.,

as Trustee

 _______________

 

SECOND SUPPLEMENTAL INDENTURE

dated as of August 23, 2019 

 

to

 

INDENTURE

dated
as of March 22, 2005

 

 

 

 

 

     

     

    

 

THIS SECOND
SUPPLEMENTAL INDENTURE, dated as of August 23, 2019 (this “Second Supplemental Indenture”), by and among Newmont
GOLDCORP Corporation (formerly known as Newmont Mining Corporation), a Delaware corporation, as issuer (the “Issuer”),
Newmont USA Limited, a Delaware corporation, as guarantor (the “Guarantor”),
and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity
but solely as trustee (the “Trustee”).

 

W I T N E S S E T H:

 

WHEREAS, the
Issuer, the Guarantor and the Trustee, as successor-in-interest to Citibank, N.A., have entered into the indenture, dated as of
March 22, 2005 (the “Base Indenture”), providing for the issuance from time to time of the Issuer’s unsecured
bonds, debentures, notes and other evidences of indebtedness in one or more series;

 

WHEREAS, the
Issuer has previously issued $600.0 million in aggregate principal amount of its 5.875% Notes due 2035, under a global note bearing
CUSIP No. 651639AE6, pursuant to the Indenture, which are currently Outstanding (the “Notes”);

 

WHEREAS, the
Issuer and Barrick Gold Corporation, a corporation existing under the laws of the Province of British Columbia, Canada, entered
into the implementation agreement, dated as of March 10, 2019, pursuant to which certain of the Guarantor’s assets, properties
and rights located in the State of Nevada were transferred (the “Joint Venture Transaction”) to Nevada Gold
Mines LLC, a Delaware limited liability company (the “JV Entity”);

 

WHEREAS, in
connection with the consummation of the Joint Venture Transaction, the JV Entity agreed to provide a full and unconditional Guaranty
on the terms and subject to the conditions set forth in the Indenture and assumed the due and punctual performance and observance
of all of the covenants and conditions of the Guarantor under the Indenture and the Notes pursuant to the first supplemental indenture,
dated as of July 1, 2019 (the “First Supplemental Indenture” and, together with the Base Indenture, the “Indenture”);

 

WHEREAS, Section
7.2 of the Indenture authorizes or permits amendments to the Indenture as set forth in Articles One and Two herein
with the consent of the Holders of a majority in aggregate principal amount of the Notes Outstanding (the “Requisite Consents”);

 

WHEREAS, the
Issuer has solicited consents from the Holders of the Notes (i) to release the JV Entity (A) as a guarantor under its Guaranty,
the Indenture and the Notes and (B) from the performance and observance of the covenants and conditions of the Guarantor under
the Indenture and the Notes (the “Proposed Guaranty Release”) and (ii) to conform the provisions of Section
8.1(b) of the Base Indenture to the corresponding provisions in the indenture governing the Issuer’s Notes due 2019, Notes
due 2022, Notes due 2039 and Notes due 2042 as described in the consent solicitation statement, dated August 16, 2019 (as amended,
supplemented or otherwise modified, the “Consent Solicitation Statement”), and set forth in Article Two
herein (the “Conforming Amendment” and, together with the Proposed Guaranty Release, the “Proposed
Amendments”);

 

    	 	1	 

     

    

 

WHEREAS, the
Issuer has obtained the Requisite Consents to the Proposed Amendments to the Indenture set forth in Articles One and Two
herein;

 

WHEREAS, each
of the Issuer and the Guarantor has been authorized by the resolutions of their respective boards of directors or a committee of
their respective boards of directors, as the case may be, to enter into this Second Supplemental Indenture;

 

WHEREAS, each
of the Issuer and the Guarantor has requested that the Trustee execute and deliver this Second Supplemental Indenture, and the
Trustee has received an Officers’ Certificate of the Issuer and an Opinion of Counsel in accordance with Sections 7.2, 7.4
and 13.5 of the Indenture; and

 

WHEREAS, pursuant
to Sections 7.2 and 7.4 of the Indenture, the Trustee is authorized to execute and deliver this Second Supplemental Indenture.

 

NOW THEREFORE,
in consideration of the premises and covenants and agreements contained herein and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, and for the equal and proportionate benefit of the Holders of the Notes,
the Issuer, the Guarantor and the Trustee hereby agree as follows:

 

ARTICLE
ONE

RELEASE
Of Guaranty

 

Effective as
of the time when the Consent Fee has been paid pursuant to the Consent Solicitation (the “Operative Time”) and
subject in all respects to Section 3.1, (i) the Guaranty of the JV Entity shall be terminated and (ii) the JV Entity shall
be fully, finally and indefeasibly released from any and all of the covenants, conditions and obligations under or in connection
with its Guaranty, the Indenture and the Notes. Effective as of the Operative Time and subject in all respects to Section 3.1,
including, for the avoidance of doubt, the payment of the Consent Fee as set forth therein, the JV Entity shall have no further
obligation, liability, duty or burden in respect of its Guaranty, the Indenture and the Notes and shall not exercise any right
or power of a guarantor under the Indenture and the Notes.

 

ARTICLE
TWO

AMENDMENTS
TO INDENTURE

 

(a) Effective
as of the Operative Time, the Indenture shall be amended by deleting Section 8.1(b) in its entirety and inserting the following
Section 8.1(b) in lieu thereof:

 

“(b)        The
Guarantor may consolidate with or merge into or sell all or substantially all of its assets to any Person (including, without limitation,
the Issuer). Notwithstanding the foregoing, the Guarantor shall not merge or consolidate with any Affiliate of the Issuer, or sell
or otherwise dispose of all or substantially all of the Guarantor’s assets, in one transaction or a series of related transactions,
to any Affiliate of the Issuer, unless:

 

    	 	2	 

     

    

 

(1)        the Person formed by or surviving any such consolidation or merger (if not the Issuer or the Guarantor) or to whom such sale
is made (if not the Issuer) (i) is a corporation, partnership, trust or limited liability company organized and existing under
the laws of the United States of America, any state thereof or the District of Columbia and (ii) assumes all the obligations
of the Guarantor under the Guaranty pursuant to a supplemental indenture in form and substance reasonably satisfactory to the Trustee;
and

 

(2)        the
Issuer delivers to the Trustee an Officers’ Certificate and an Opinion of Counsel addressed to the Trustee stating that such
consolidation, merger or transfer and such supplemental indenture comply with this Indenture.

 

The
preceding clauses (1) and (2) shall not apply to any merger or consolidation of the Guarantor with the Issuer or with
any Person other than an Affiliate of the Issuer, or to any sale or other disposition of all or substantially all of the assets
of the Guarantor, in one transaction or a series of related transactions, to the Issuer or to any Person other than an Affiliate
of the Issuer.

 

The
Guarantor shall be deemed released from all of its obligations under this Indenture and the Guaranty, and the Guaranty shall terminate,
without any action required on the part of the Trustee or any Holder of the Securities, upon the sale or other disposition of a
majority of the total voting power of the capital stock of or other ownership interests in the Guarantor entitled to vote generally
in the election of directors (by merger, consolidation, the sale or other disposition of the capital stock of or other ownership
interests in the Guarantor, or otherwise), in one transaction or a series of related transactions, to any Person other than the
Issuer or an Affiliate of the Issuer.

 

The
Guarantor shall be deemed released from all of its obligations under this Indenture and the Guaranty, and the Guaranty shall terminate,
without any action required on the part of the Trustee or any Holder of the Securities, upon the sale or other disposition of all
or substantially all of its assets to any Person other than the Issuer or an Affiliate of the Issuer.”.

 

(b)           Effective
as of the Operative Time, Section 1.1 of the Indenture shall be amended by adding the following new definition in alphabetical
order:

 

““Affiliate”
of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect
common control with such specified Person. For the purposes of this definition, “control” when used with respect
to any specified Person means the power to direct the management and policies of such Person, directly or indirectly, whether through
the ownership of voting securities, by contract or otherwise, and the terms “controlling” and “controlled”
have meanings correlative to the foregoing; provided, however, that the existence of a management contract by the
Issuer or an Affiliate of the Issuer to manage another entity shall not be deemed to be control.”.

 

(c)           Any
provision contained in the Notes that relates to any provision of the Indenture as amended by this Article Two shall likewise
be amended so that any such provision contained in the Notes will conform to, and be consistent with, any provision of the Indenture
as amended hereby.

 

    	 	3	 

     

    

 

ARTICLE
THREE

MISCELLANEOUS

 

SECTION
3.1. Reference to and Effect on the Indenture. On and after the effective date of this Second Supplemental Indenture, each
reference in the Indenture to “this Indenture,” “hereunder,” “hereof” or “herein”
shall mean and be a reference to the Indenture, as supplemented and amended by this Second Supplemental Indenture, unless the context
otherwise requires. This Second Supplemental Indenture shall be effective immediately upon execution (the “Effective Time”).
The Proposed Amendments effected by this Second Supplemental Indenture and set forth herein shall not become operative if the Issuer
does not pay, or cause to be paid, (a) the Consent Fee (as defined in the Consent Solicitation Statement) to The Depository Trust
Company for the benefit of the consenting Holders in accordance with the terms set forth in the Consent Solicitation Statement
and (b) the reasonable and documented fees, disbursements and out-of-pocket expenses incurred by Shearman & Sterling LLP, counsel
to certain Holders, in accordance with and subject to any prior agreements. Upon satisfaction of the foregoing clauses (a) and
(b) of this Section 3.1, the Issuer shall certify to such satisfaction in an Officers’ Certificate delivered to the
Trustee.

 

SECTION
3.2. Integral Part. This Second Supplemental Indenture constitutes an integral part of the Indenture.

 

SECTION
3.3. Adoption, Ratification and Confirmation. Subject to Section 3.1, (i) the Indenture, as supplemented and amended
by this Second Supplemental Indenture, is in full force and effect and is in all respects hereby adopted, ratified and confirmed,
(ii) every Holder of the Notes heretofore authenticated and delivered under the Indenture shall be bound by the Indenture as amended
hereby and (iii) in the case of a conflict between the Indenture and this Second Supplemental Indenture, the provisions of this
Second Supplemental Indenture shall control (absent a manifest error).

 

SECTION
3.4. General Definitions. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in
the Indenture.

 

SECTION
3.5. Counterparts. This Second Supplemental Indenture may be executed in any number of copies or counterparts, each of which
will be an original, and all such counterparts together shall represent the same agreement. The exchange of copies of this Second
Supplemental Indenture and of signature pages by facsimile or “.pdf” transmission shall constitute effective execution
and delivery of this Second Supplemental Indenture as to the parties hereto and may be used in lieu of the original Second Supplemental
Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or “.pdf” shall be deemed to
be their original signatures for all purposes.

 

SECTION
3.6. Headings. Titles of articles or sections of this Second Supplemental Indenture are for convenience of reference only,
are not to be considered a part of this Second Supplemental Indenture and will in no way modify or restrict any of the terms or
provisions hereof.

 

    	 	4	 

     

    

 

SECTION
3.7. Conflict with Trust Indenture Act. If any provision of this Second Supplemental Indenture limits, qualifies or conflicts
with a provision of the Trust Indenture Act that is required under the Trust Indenture Act to be a part of and govern the Indenture,
the provision required under the Trust Indenture Act shall control. If any provision of this Second Supplemental Indenture modifies
or excludes any provision of the Trust Indenture Act that may be so modified or excluded, such provision under the Trust Indenture
Act shall be deemed to apply to the Indenture as so modified or excluded, as the case may be.

 

SECTION
3.8. Severability. In case any provision of this Second Supplemental Indenture, the Indenture as supplemented by this
Second Supplemental Indenture or any of the Notes is invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions will not in any way be affected or impaired thereby.

 

SECTION 3.9.
Benefits of Supplemental Indenture. Nothing in this Second Supplemental Indenture, express or implied, shall give to any
Person (other than the parties hereto and their successors hereunder and the Holders) any benefit or any legal or equitable right,
remedy or claim under this Second Supplemental Indenture. Notwithstanding anything to the contrary in this Second Supplemental
Indenture, the JV Entity shall be a third party beneficiary of this Second Supplemental Indenture and shall be entitled to rely
on this Second Supplemental Indenture, including Article One.

 

SECTION
3.10. GOVERNING LAW. THIS SECOND SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS
OF THE STATE OF NEW YORK.

 

SECTION
3.11. No Recourse against Others. No director, officer, employee or shareholder as such of the Issuer or the Guarantor shall
have any liability for any obligations of the Issuer and the Guarantor under this Second Supplemental Indenture or for any claim
based on, in respect of or by reason of such obligations or their creation.

 

SECTION
3.12. Successors. All agreements of the Issuer and the Guarantor in this Second Supplemental Indenture shall bind their
respective successors and permitted assigns. All agreements of the Trustee in this Second Supplemental Indenture shall bind its
successors and permitted assigns.

 

SECTION
3.13. Trustee Not Responsible for Recitals. The recitals herein contained are made by the Issuer and the Guarantor and not
by the Trustee, and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representation as to
the validity or sufficiency of this Second Supplemental Indenture.

 

[Signature Pages Follow]

 

    	 	5	 

     

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this Second Supplemental Indenture to be duly executed as of the date first written above.

 

	 	NEWMONT GOLDCORP CORPORATION,
	 	as Issuer
	 	 
	 	 
	 	By:	 /s/ Joshua P. Hallenbeck
	 	 	Name: Joshua P. Hallenbeck
	 	 	Title: Vice President, Finance and Treasurer
	 	 
	 	 
	 	NEWMONT USA LIMITED,
	 	as Guarantor
	 	 
	 	 
	 	By:	 /s/ Joshua P. Hallenbeck
	 	 	Name: Joshua P. Hallenbeck
	 	 	Title: Vice President, Finance and Treasurer

 

[Signature
Page—Second Supplemental Indenture—2035 Notes]

 

     

     

    

 

	 	The Bank of New York Mellon Trust Company, N.A.,
	 	not in its individual capacity but solely as Trustee
	 	 
	 	 
	 	By:	/s/ Karen Yu
	 	 	Name: Karen Yu
	 	 	Title: Vice President

 

[Signature
Page—Second Supplemental Indenture—2035 Notes]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]